Table 4.
Mean baseline values, within-group changes after 3–months and the net between-group differences for the change for cardiac parameters in Allo-HCT and Control groups.
| Measure | Allo-HCT | Control | Δ net difference | Group, | Time, | Group x Time, |
|---|---|---|---|---|---|---|
| (HCT vs. Con) | p | p | p | |||
| Cardiac biomarkers | ||||||
| cTn–I, ng.L −1 | ||||||
| Baseline | 4.6 ± 4.2 | 2.8 ± 1.2 | ||||
| 3–months | 5.4 ± 5.7 | 2.9 ± 1.1 | ||||
| Δ | 0.8 (−1.8, 3.4) | 0.1 (−2.8, 3.0) | 0.71 (−3.2, 4.6) | 0.14 | 0.63 | 0.72 |
| BNP, ng.L − 1 | ||||||
| Baseline | 40.5 ± 32.0 | 33.2 ± 22.9 | ||||
| 3–months | 54.3 ± 35.6 | 31.7 ± 28.5 | ||||
| Δ | 13.8 (−3.2, 30.8) | −1.6 (−21.2, 18.1) | 15.4 (−10.6, 41.3) | 0.22 | 0.34 | 0.24 |
| Resting echocardiography | ||||||
| LVEF, % | ||||||
| Baseline | 54.7 ± 5.5 | 59.5 ± 5.7 | ||||
| 3–months | 56.1 ± 3.8 | 57.6 ± 4.4 | ||||
| Δ | 1.4 (−1.3, 4.1) | −1.8 (−4.9, 1.3) | 3.2 (−0.9, 7.3) | 0.065 | 0.84 | 0.12 |
| GLS, % | ||||||
| Baseline | −17.8 ± 2.0 | −20.0 ± 2.4 | ||||
| 3–months | −17.3 ± 1.5 | −19.4 ± 1.9 | ||||
| Δ | 0.5 (−0.6, 1.6) | 0.6 (−0.7, 2.0) | −0.1 (−1.8, 1.6) | 0.001 | 0.18 | 0.90 |
| Resting CMR | ||||||
| HR, beats.min −1 | ||||||
| Baseline | 81 ± 12 | 66 ± 9 | ||||
| 3–months | 84 ± 6 | 63 ± 9 | ||||
| Δ | 3 (−5, 10) | −3 (−11, 5) | 6 (−5, 16) | <0.001 | 0.98 | 0.30 |
| SVI, ml.m −2 | ||||||
| Baseline | 50.0 ± 7.4 | 54.2 ± 9.2 | ||||
| 3–months | 47.6 ± 9.0 | 53.7 ± 8.3 | ||||
| Δ | −2.4 (−5.2, 0.3) | −0.5 (−3.4, 2.4) | −1.9 (−5.9, 2.1) | 0.14 | 0.14 | 0.33 |
| CI, L.min −1 .m −2 | ||||||
| Baseline | 4.0 ± 0.8 | 3.6 ± 0.6 | ||||
| 3–months | 4.0 ± 0.9 | 3.4 ± 0.5 | ||||
| Δ | 0.0 (−0.4, 0.4) | −0.2 (−0.6, 0.2) | 0.2 (−0.4, 0.7) | 0.032 | 0.42 | 0.58 |
| LVEF, % | ||||||
| Baseline | 53.4 ± 5.5 | 56.5 ± 2.6 | ||||
| 3–months | 53.2 ± 4.3 | 56.2 ± 3.2 | ||||
| Δ | −0.2 (−3.2, 2.8) | −0.3 (−3.4, 2.8) | 0.1 (−4.2, 4.4) | 0.026 | 0.80 | 0.96 |
| RVEF, % | ||||||
| Baseline | 55.5 ± 3.7 | 52.4 ± 4.7 | ||||
| 3–months | 55.6 ± 2.9 | 52.8 ± 4.3 | ||||
| Δ | 0.1 (−1.9, 2.1) | 0.5 (−1.6, 2.6) | −0.3 (−3.2, 2.5) | 0.054 | 0.67 | 0.81 |
| Exercise CMR | ||||||
| HR peak , beats.min −1 | ||||||
| Baseline | 136 ± 16 | 147 ± 13 | ||||
| 3–months | 130 ± 16 | 146 ± 14 | ||||
| Δ | −6 (−12, 1) | −2 (−8, 6) | −4 (−14, 5) | 0.029 | 0.14 | 0.37 |
| SVI peak , ml.m −2 | ||||||
| Baseline | 57.9 ± 10.0 | 63.8 ± 11.6 | ||||
| 3–months | 52.9 ± 11.0 | 63.2 ± 9.6 | ||||
| Δ | −5.0 (−8.1, −1.9)** | −0.6 (−3.9, 2.7) | −4.4 (−8.9, 0.2) | 0.063 | 0.017 | 0.058 |
| CI peak , L.min −1 .m −2 | ||||||
| Baseline | 7.8 ± 1.5 | 9.4 ± 2.1 | ||||
| 3–months | 6.8 ± 1.3 | 9.2 ± 1.7 | ||||
| Δ | −1.0 (−1.5, −0.5)*** | −0.2 (−0.8, 0.2) | −0.8 (−1.6, 0.0) | 0.004 | 0.002 | 0.042 |
| LVEF peak , % | ||||||
| Baseline | 59.2 ± 4.3 | 64.1 ± 3.7 | ||||
| 3–months | 57.3 ± 5.4 | 64.1 ± 3.6 | ||||
| Δ | −1.9 (−3.6, −0.2)* | 0.0 (−1.8, 1.8) | −1.9 (−4.4, 0.6) | 0.001 | 0.13 | 0.14 |
| RVEF peak , % | ||||||
| Baseline | 62.4 ± 3.0 | 61.9 ± 5.5 | ||||
| 3–months | 59.2 ± 4.5 | 62.8 ± 5.0 | ||||
| Δ | −3.2 (−5.3, −1.1)** | 0.9 (−1.3, 3.1) | −4.1 (−7.2, −1.0) | 0.37 | 0.14 | 0.01 |
All baseline and 3–month values are unadjusted means ± SDs; all within-group changes are unadjusted mean (95% CI) and expressed as absolute change from baseline. Mean net differences were calculated by subtracting the within–group changes from baseline in the control group from the within–group change from baseline in the allo-HCT group after 3 months. *p < 0.05, **p < 0.01, ***p < 0.001 vs. baseline. BNP, brain natriuretic peptide; CI, cardiac index; cTn-I, troponin I; CMR, cardiac magnetic resonance imaging; GLS, global longitudinal strain; HR, heart rate; LVEF, left-ventricular ejection fraction; RVEF, right-ventricular ejection fraction; SVI, stroke volume index.